Myles Helfand

Executive Editor

Myles is the executive editor and general manager of TheBody/TheBodyPro. A career journalist and editor, Myles joined TheBody in 2001 as a part-time copyeditor. He has since established himself as a leading journalist and content strategist on HIV-related issues, authoring hundreds of articles and editing hundreds more -- and accumulating an ever-growing mountain of HIV conference badges along the way.

Latest by Myles Helfand

This Week in HIV Research: A Test of Resistance

May 16, 2019: The dwindling value of baseline genotype testing; severe insomnia and cardiovascular disease; cardiovascular risk stratified by sex among people over 50; the persistence of racial disparities among women diagnosed with HIV.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Better Serving the Underserved

May 9, 2019: HIV care retention and viral suppression among transgender women; heating opioid use equipment to curb HIV transmission; managing HIV outbreaks among people who are homeless; improving viral suppression among people who use substances.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Unexpected Outcomes

May 2, 2019: patient-centered care model improves viral suppression; subpar immune responses when baseline CD4 tops 500; when CD4 plummets despite viral suppression; vaccination, immunoglobulin, and hepatitis A exposure.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Disparities Drive the Epidemic

April 25, 2019: stigma and viral load among African-American women; U.S. HIV incidence sans racial disparities; the care continuum is failing young MSM; a moment of reckoning regarding HIV among U.S. youth.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: From PrEP to Treatment, There's Always More to Learn

April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: HIV Is Not an Obstacle

April 11, 2019: acute syphilis and virologic control; neuropsychological performance after switching off efavirenz; structural LGBTQ stigma and HIV criminalization in U.S. states; lung cancer resection surgery in people with HIV.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Fentanyl Smooths the Path for HIV

April 4, 2019: what’s driving the HIV outbreak in northeastern Massachusetts; race-gender HIV disparities among Baltimore sex workers; high PrEP interest, low awareness among southern black women; naltrexone implants for opioid dependence.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Additional Nuance on Pregnancy and Antiretrovirals

Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Exorcizing Our PrEP Demons

Experts push for normalization of PrEP; U.S. HIV transmission rates across the care continuum; sociodemographic disadvantage and HIV drug resistance; real-world success of integrase inhibitors for treatment-experienced people.

By Myles Helfand

Tonia Poteat's Career Started With a Piece of Folded Paper

Looking back on Poteat’s professional arc, it can appear as though her path toward a leadership role in HIV care was always clear. But there have been plenty of twists in that path.

By Myles Helfand